Scroll
Our monthly tracker report aims to provide a concise update for busy health tech professionals on the many factors influencing your work.
Here you will find a breakdown of deals, developments and opportunities from the last 30 days; and insight and opinion from leading thinkers in the field.
We hope you find something useful and/or inspiring below – and welcome any feedback about what else you’d like to see included. And don’t forget you can find daily updates on the health tech sector on our website.
Many thanks for your interest in Health Tech World.
Andrew Mernin
Editorial director, Health Tech World
andrew@aspecthealthmedia.com
Value: $20 million
Stage: Series B round (announced 29 July 2026)
Solution: Cambridge-based end-to-end imaging platform providing AI-powered analysis and precision endpoints for clinical trials in lung and heart disease, with the funds supporting an AI imaging laboratory housing its 3D chest imaging foundation model and expansion into asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity.
Investors: Molten Ventures (lead), with existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension.
Significance: A rare UK Series B in “clinical plumbing” AI — capital flowing into tools embedded in pharma R&D workflows rather than consumer-facing apps, and a sign that imaging AI companies with biopharma revenue can still raise in a selective market.
Read more: https://theaiinsider.tech/2026/08/07/qureight-closes-20m-series-b-financing/
Value: $19 million
Stage: Growth round (announced 24 July 2026)
Solution: AI-powered COPD diagnostics — its N-Tidal Diagnose test has patients breathe into a handheld device for 75 seconds, capturing a CO₂ waveform that AI models analyse, cutting test time from around an hour to under five minutes, with funds going to accelerating NHS and European rollout and US market entry.
Investors: New investor Cross-Border Impact Ventures alongside returning backers BGF, Airstream Capital and Foresight Group.
Significance: A UK respiratory AI diagnostics story with direct NHS deployment — evidence that investors will back regulated point-of-care AI where the efficiency case (clinician time saved per test) is concrete and measurable.
Read more:
Value: $120 million
Stage: Series D round (announced 21 July 2026)
Solution: Autonomous revenue cycle management platform automating billing, claims processing and collections for healthcare providers, using AI agents to attack the $280 billion spent annually on US healthcare RCM.
Investors: Sixth Street Growth (lead), with participation from Oak HC/FT, 8VC and Y Combinator.
Significance: The round tripled Candid’s valuation from its February 2025 Series C, on the back of 190% year-over-year contracted revenue growth — emblematic of the current megadeal concentration in “boring” administrative AI, where ROI is provable and agentic automation is displacing labour-heavy incumbents.
Value: $25+ million
Stage: Growth round (announced 15 July 2026)
Solution: Remote physical examination technology built on FDA-cleared devices, repositioning as an AI-first clinical enablement platform for chronic and complex disease, embedding AI-powered remote care across congestive heart failure, COPD, oncology and post-acute pathways.
Investors: Insight Partners (lead), alongside HOOP, OliveTree, OrbiMed, Qumra Capital, Qualcomm Ventures and others, announced together with a new CEO appointment.
Significance: Shows established telehealth-era companies re-raising by pivoting from episodic virtual visits toward regulated AI software-as-a-medical-device — with investor conviction resting on FDA-cleared algorithms rather than telehealth volumes.
Value: $16.2 million
Stage: Oversubscribed Series A round (announced 21 July 2026)
Solution: AI-native cardiovascular care platform connecting payers, providers and patients through a unified data and workflow layer for earlier risk detection, currently supporting more than 600 cardiology providers across 11 US states, with deployed programmes showing over 40% reductions in ED visits and inpatient admissions.
Investors: Co-led by 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels.
Significance: Illustrates the value-based specialty care thesis moving into cardiology — VCs backing AI platforms that take on outcomes risk in the single costliest disease area in US healthcare, with utilisation data now expected even at Series A.
Value: $25 million
Stage: Series B round (disclosed 16 July 2026, bringing total funding to $55 million)
Solution: AI agents deployed inside hospitals to tackle operational problems such as long wait times, missed follow-ups and paperwork backlogs.
Investors: Khosla Ventures (lead).
Significance: Part of the wave of “agentic AI” startups moving beyond diagnostics into hospital operations — investors betting that autonomous agents handling workflow gaps (rather than clinical decisions) offer a faster, lower-regulatory-risk route to revenue inside health systems.
Value: $32.5 million (combined)
Stage: Seed and Series A financing (announced 13 July 2026)
Solution: A technology platform empowering nurse practitioners to start and scale their own independent primary care practices, providing everything from billing and insurance infrastructure to AI-powered workflow automation, with a network of more than 70 provider-owned practices and 35,000+ patient visits in the past year, making it the fastest-growing primary care network in Arizona and Washington.
Investors: Series A led by Oak HC/FT, with participation from existing investors First Round Capital and Zigg Capital; earlier backers include Homebrew, Pathlight Ventures, Wischoff Ventures and Go Global Ventures.
Significance: A twist on the AI-in-primary-care thesis — rather than replacing clinicians, VCs are funding infrastructure that lets nurse practitioners own their practices, using AI to remove the administrative burden that makes independent practice unviable, against a backdrop where more than 100 million Americans lack access to a primary care provider.
Value: $10 million
Stage: Series A round (announced 28 July 2026), bringing total funding to nearly $18 million since its 2023 founding
Solution: A smart toilet sensor tracking gut health, hydration and urinary function — the device attaches to any standard toilet and uses computer vision and AI to analyse bathroom habits and build personalised health insights over time, co-founded by former Whoop co-founder and CTO John Capodilupo, and aimed at everyday users plus the 25–45 million Americans living with conditions like IBS.
Investors: Will Ventures (lead), with participation from Emerson Collective, Workshop, LEAD VC, Salt VC, Accomplice, Moxxie, Ventures Together, Symphony, Felix Capital, Cosmic Venture Partners, Offscript, V1.VC and Morrison Seger.
Significance: Extends the passive health monitoring wave pioneered by Whoop and Oura into digestive health — investors betting that continuous gut-health tracking is the logical successor to wrist-worn wearables, and that proprietary consumer health datasets create defensibility in the AI era. Also a lighter, more consumer-facing counterpoint to the clinical AI deals above.
Value: US$1.1bn (all-cash transaction offering US$18.90 per share; announced 10 August 2026)
Deal type: Strategic acquisition / public company takeover
Solution: Varex Imaging develops X-ray imaging components, including tubes, digital detectors and high-voltage connectors. Its technology supports medical diagnostics alongside security, industrial inspection and scientific applications.
Acquirer: Teledyne Technologies.
Significance: The deal expands Teledyne’s healthcare imaging portfolio and adds technology used across diagnostic X-ray systems. The companies expect the transaction to close in early 2027, subject to shareholder and regulatory approvals.
Value: US$105m in cash (announced 4 August 2026; expected to close in the third quarter)
Deal type: Strategic digital health acquisition
Solution: Cylinder Health provides virtual-first digestive healthcare for conditions including irritable bowel syndrome and inflammatory bowel disease. Its platform combines personalised courses, microbiome testing, lifestyle support and access to specialist care teams.
Acquirer: Hinge Health.
Significance: The acquisition takes Hinge beyond musculoskeletal and migraine care into gastrointestinal health. Cylinder’s platform is expected to be integrated into Hinge’s application, creating a broader virtual-care offering for employers and health plans.
Value: Undisclosed (completed 30 July 2026)
Deal type: Private equity acquisition / investment
Solution: France-based padoa operates an occupational health technology platform connecting health services, professionals, employers and employees. Its software supports health records, prevention programmes, appointments and workplace health management.
Acquirer: Thoma Bravo.
Significance: The deal gives padoa the backing of a major software investor as it looks to expand its occupational health platform in France and elsewhere in Europe. It also reflects increasing private equity interest in specialised healthcare software with recurring institutional customers.
.
Value: Undisclosed (completed 23 July and announced 28 July 2026)
Deal type: Strategic health IT acquisition
Solution: Telemetrix RPM provides remote patient monitoring and chronic care management through technology integrated with Epic and other electronic health record systems.
Acquirer: Nexus, formerly Nexus Bedside.
Significance: The acquisition extends Nexus’s clinical care operating system beyond hospitals and into patients’ homes. It creates a more continuous platform through which health systems can coordinate inpatient, post-discharge and chronic care.
Value: Approximately US$1.5bn in enterprise value (announced 20 July 2026; consideration primarily in Tempus shares, with an option to pay up to 50 per cent in cash)
Deal type: Strategic acquisition / public company merger
Solution: Personalis develops cancer genomics and minimal residual disease testing. Its NeXT Personal platform creates an individual genetic signature from a patient’s tumour and uses blood tests to monitor for remaining or returning cancer.
Acquirer: Tempus AI.
Significance: The deal combines Personalis’s genomic testing technology with Tempus’s clinical data, artificial intelligence and commercial reach. It could strengthen Tempus’s position across the cancer pathway, from diagnosis and treatment selection to recurrence monitoring.
Value: Undisclosed (announced 15 July 2026)
Deal type: Strategic healthcare software acquisition
Solution: Concert develops technology that translates clinical and administrative policies into machine-readable rules that can inform healthcare payment decisions in real time.
Acquirer: Lyric.
Significance: Concert’s technology will be incorporated into Lyric’s healthcare decision intelligence platform. The combination is intended to help health plans apply clinical policy more consistently while identifying inaccurate, duplicate or non-compliant claims
Value: Undisclosed (announced 14 July 2026)
Deal type: Strategic healthcare AI acquisition
Solution: Dialog Health provides a healthcare-focused two-way texting and Rich Communication Services platform. Its technology supports appointment reminders, confirmations, patient recall, surveys, billing follow-up and staff communications.
Acquirer: SpinSci.
Significance: The acquisition combines Dialog Health’s text-based patient communications with SpinSci’s voice AI and patient-access technology. The resulting platform is intended to give health systems a unified way to manage patient engagement across voice and text channels.
Value: €8.6m upfront, comprising €8.3m in cash and 75,000 VitalHub shares, plus potential earn-outs of up to €4.5m (announced and completed 13 July 2026)
Deal type: Strategic digital health acquisition
Solution: Finland-based Buddy Healthcare provides digital care pathway software used to coordinate patients before and after procedures. Its platform supports patient communication, preparation, remote follow-up and workflow automation.
Acquirer: VitalHub.
Significance: The acquisition adds another patient-flow and care-coordination product to VitalHub’s healthcare software portfolio while strengthening its presence in Finland, the UK and other European markets.
With that in mind, we asked Health Tech leaders in the UK and US: What regulatory or reimbursement shift would most accelerate adoption of tools like yours?
Here’s what they told us.
Jason Harries, chief commercial officer, Insource
Across the NHS, many trusts and health boards still manage elective and cancer pathways, waiting lists, operational performance and statutory reporting through spreadsheets, bespoke internal builds and EPR modules never designed for end‑to‑end workflow management.
That fragility drives missed RTT and cancer targets, migration risk during EPR change and income exposure when statutory reporting breaks.
The regulatory and reimbursement shift that would most accelerate adoption of tools like Patient Pathway Plus and Health Data Enterprise is recognising operational data platforms as reimbursable infrastructure and rewarding investment in proven pathway and reporting solutions.
When income and compliance depend on data quality and continuity, modernising away from spreadsheets and generic EPR workflows becomes urgent.
Dr. Yousuf J. Ahmad, CEO & president of AssureCare
The shift I’d most like to see is policy recognising what frontline healthcare organizations already know: operational technology and clinical technology are the same investment.
When providers spend less time chasing claims and reconciling denials, they spend more time with patients.
Reimbursement models that make it easier to invest in tools that reduce administrative burden, not just clinical tools, would accelerate adoption and, more importantly, improve the care those organizations can deliver.
Ioannis Chronakis, CEO, Deontics
The shift needs to happen in two areas: connecting national strategies to point of care funding, and regulation that requires EHR systems to offer timely, frictionless access to data.
When software aligns with a national strategy, such as the National Cancer Plan, and carries independent evidence of savings or improved outcomes, there should be a clear mechanism for a hospital or primary care organisation to be reimbursed for adopting it. The benefit demonstrated often sits upstream, yet the point of care is asked to pay.
Alongside that, procurement rules should oblige EPR suppliers and trusts to give approved third-party systems transparent and timely data access, as this is often the main barrier to delivering a proven benefit.
Baha Zeidan, CEO of Azalea Health
The add of Value Based Care does and will need Analytics to compile data. When VBC becomes final in 2030 and even now, it will help accelerate adoption of Azalea because we can support the necessary analytics. This affects both rural health clinics and ambulatory clinics. VBC requires data to be reported to CMS, and Azalea Analytics can do that. The RHT Progam also requires specific reporting for VBC initiatives for rural providers, which Azalea Analytics can do.
Kieran Daly, co-founder & general manager, HealthBeacon
I believe the biggest shift would be creating clearer pathways for digital tools to progress into standard care. The innovation is there; healthcare systems run lots of pilots, but relatively few technologies progress from pilot to widespread adoption. This is because procurement often favours large, established companies, making it difficult for innovative companies to compete.
More flexible procurement models would make it easier for healthcare providers to adopt new, innovative technologies. Of course, safeguards should always be an integral part of the process, but they cannot become barriers that prevent patients benefitting from technologies that have proven positive outcomes.
Oliver Norman, chief revenue officer, Nomia
What would move the needle most isn’t simply more or less regulation, but the need for greater clarity and consistency.
As pharmaceutical organisations adopt new technologies and expand their supplier networks, procurement teams must keep pace with rapidly evolving governance and reporting requirements – and they need greater visibility to do it.
This is where procurement platforms combining AI with human oversight can make a meaningful difference: bringing thousands of suppliers into one place so organisations can identify trusted vendors, keep documentation current and demonstrate compliance across different audit and regulatory requirements.
The growing pressure to manage supplier standards across increasingly complex global markets is making this level of visibility, accountability and control essential.”
Ram Rajamaran, healthcare & life sciences industry leader at Quantexa
To accelerate AI adoption, policy frameworks must focus on building frontline trust through on-the-job workforce training and strict open-standard requirements.
The NHS is increasingly recognising that true productivity gains depend on embedding AI capability directly into everyday roles, not layering extra tools on top of an already stretched workforce.
Unlocking this capability requires innovative approaches, like two-way secondments between the NHS and industry, to accelerate shared learning and build real-world confidence.
The NHS shouldn’t have to choose between innovation and control.
By establishing regulatory standards that enforce interoperability across vendor platforms while upskilling staff, regulators can build clinician trust and pave a clear operational path for real-world deployment.
Dr Tom Davis, UK country manager and medical director, Livi UK
The biggest lever regulators could pull is a clear national reimbursement pathway for digital consultations.
In Germany, any citizen can access a reimbursed digital GP consultation regardless of geography. Sweden has taken a similar approach, and it’s produced one of Europe’s most digitally advanced healthcare economies.
In the UK, digital access still depends heavily on individual practice and ICB decisions rather than a consistent national framework.
Removing that inconsistency – so digitally enabled care is reimbursed the same way wherever a patient lives – would do more to accelerate adoption than any single piece of technology.
The University of Pennsylvania, the University of Delaware and several collaborating universities have been awarded $21.5 million over five years by the US National Science Foundation to establish the NSF AI Institute for Human-AI Cooperation, bringing together over 40 partners across academia, industry and government. Announced in late July 2026, the institute is designed to support, not replace, human decision-making in healthcare, with its director describing the aim as transforming AI into an “adaptive teammate” for clinicians. The award matters for health tech because it targets the human-AI interaction layer — exactly where clinical AI deployments currently succeed or fail — and creates a large academic-industry testbed for co-operative AI tools before they reach commercial products.
The National Institute for Health and Care Research has awarded £1.65 million to 17 projects supporting the early-stage development of quantum technologies, announced 29 July 2026. Funded through the NIHR’s Invention for Innovation (i4i) Funding At the Speed of Translation (FAST) scheme, the awards connect leading UK quantum research with clinical expertise and NIHR infrastructure to help promising technologies move towards NHS use, with projects spanning cancer imaging, home monitoring and prediction of life-threatening events. This is a signal of where the next wave of health tech beyond AI may come from — and follows the government’s March 2026 package aiming to make the UK the first country to roll out quantum computers at scale.
Massachusetts General Hospital has been awarded an ARPA-H contract worth up to $25.8 million over five years, announced 21 July 2026, to develop personalised genomic medicines for rare genetic vascular diseases under the agency’s THRIVE (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicine) programme. The award — part of a wider THRIVE round providing up to $160 million to organisations developing personalised genetic medicines — reflects the milestone-gated, DARPA-style funding model reshaping US health innovation: platform technologies funded to become repeatable manufacturing and delivery infrastructure rather than one-off therapies.
London and Cambridge-based Promatix Biosciences has been awarded a grant (value undisclosed) under the Innovate UK Biomedical Catalyst 2025 industry-led R&D competition, announced 28 July 2026, to advance its lead programme PBS293-exatecan, a first-in-class EGFR × EphA2 cis-bispecific antibody-drug conjugate for colorectal cancer and other solid tumours. The non-dilutive funding covers manufacturing scale-up, preclinical proof-of-concept studies and IND-enabling safety work. It’s a live example of the UK’s £25 million Biomedical Catalyst acting as the de-risking bridge between data-driven drug design platforms and private investment — the same investor appetite for next-generation ADCs seen in your Sidewinder example, but at grant stage.
The Gates Foundation and OpenAI have jointly committed $50 million in funding, technology and technical support to Horizon 1000, an initiative to equip 1,000 primary healthcare clinics and their surrounding communities with AI tools by 2028, starting in Rwanda. Launched in January 2026, the programme gained fresh momentum in July when Bill Gates visited Rwanda to review the rollout, with tools designed to support rather than replace health workers — strengthening diagnosis, resource allocation and clinical decision-making in systems with limited staff and equipment. For health tech, it’s the highest-profile test yet of whether frontier AI models can operate safely at the frontline of primary care in low-resource settings.
Belgian healthtech firm Azalea Vision was selected for the EU’s highly competitive European Innovation Council Accelerator programme in early July 2026, securing up to €7.5 million — a €2.5 million grant plus a planned €5 million equity investment — to move its medical-grade smart contact lens into clinical trials. The lens corrects complex vision issues such as irregular corneas while functioning as a continuous, non-invasive tear biosensor. The award illustrates the EU’s blended grant-plus-equity model for deep-tech medtech, where MedTech and healthcare account for around 35% of funded EIC Accelerator projects.
The NIHR has awarded £47.8 million for equipment to streamline clinical trial delivery across 51 NHS trusts and 79 primary care organisations in England — from spirometers and ECG machines to high-tech scanners and mobile research vans. The award is funded through the government-pharma VPAG Investment Programme partnership and forms part of the Life Sciences Sector Plan ambition to speed up clinical trials and get patients into studies sooner. Like your NYU CTSA example, this is connective-tissue funding: it builds the physical and data infrastructure on which commercial trials, decentralised study methods and AI-enabled recruitment tools will run across the NHS
Washington University in St. Louis’s AI for Health Institute has awarded nearly $300,000 in seed grants — up to $50,000 per project for one-year exploratory studies — across projects spanning global child nutrition, childhood obesity, interventional radiology, radiation oncology, stem cell biology and musculoskeletal health, announced June 2026. The programme, launched in 2025, deliberately pairs AI researchers with clinical domain experts to pursue interdisciplinary work. Small in dollar terms but worth watching as a model: these institutional seed schemes are where the pipeline of clinically-grounded health AI projects — and future spinouts — typically starts.
GSK has entered a research collaboration with UK biotech Relation Therapeutics worth up to $110 million to generate large-scale human cellular datasets and train AI models for identifying new drug targets. Relation will use laboratory experiments alongside single-cell and spatial transcriptomics to produce high-quality biological data, which will then be used to train its AI systems for drug discovery. The collaboration builds on an earlier GSK–Relation relationship and is intended to improve the ability to identify disease-relevant targets and ultimately accelerate the development of new medicines.
Significance: Illustrates a growing shift in AI-enabled drug discovery from simply applying bigger models to existing datasets towards generating proprietary, high-quality biological data specifically designed to make AI models more useful.
Samsung Electronics and Lark Health have announced a multi-year strategic partnership to bring AI-powered preventive and chronic-care programmes to older adults through Samsung Health. From Q3 2026, eligible users will be able to access Lark’s AI health coaching and chronic-disease programmes through Samsung’s ecosystem, including connected devices such as Galaxy Watch and Galaxy Ring. The partnership will also use Medicare pathways including the Medicare Diabetes Prevention Program and the new ACCESS model to make eligible services available without additional out-of-pocket costs.
Significance: Shows consumer technology companies moving beyond health tracking towards directly embedded, AI-enabled prevention and chronic-care services, while linking device ecosystems with healthcare reimbursement.
Novant Health has partnered with K Health to launch an AI-enabled, 24/7 virtual primary-care model across North and South Carolina. K Health’s clinical AI will conduct pre-visit health screening, gather patients’ symptoms and concerns, and provide clinicians with a structured summary before the virtual consultation. The collaboration will also introduce PatientGPT, integrated into Novant’s electronic medical record, to provide personalised health guidance and connect patients to Novant clinicians or appointments when appropriate.
Significance: Represents a move from standalone digital-health tools towards AI being embedded directly into the health-system workflow, with the technology handling information gathering and navigation while clinicians remain responsible for care.
UCSF Health, Kleiner Perkins and Doerr Capital have launched UCSF Health Converge, a new model for developing and validating healthcare AI inside a major academic health system. Selected companies will work directly with UCSF clinicians, operators and technology leaders to build AI tools within real clinical workflows, technology systems and operational environments before scaling them more broadly. The programme is explicitly designed to address the gap between promising AI technology and successful implementation in real-world healthcare.
Significance: Signals a more mature approach to health AI innovation in which hospitals are becoming co-development environments—not simply customers—helping startups validate clinical usefulness, workflow integration and scalability before deployment.
Proximie has signed a multi-year partnership with UC San Diego Health to deploy its surgical intelligence platform across 44 operating rooms and procedure rooms at four hospital sites, while jointly developing next-generation multimodal AI for perioperative care. UC San Diego Health will serve as a clinical, technical and operational co-development environment, with the collaboration using NVIDIA’s open AI models and development frameworks. The goal is to move beyond simply digitising operating rooms towards systems that can capture and interpret information across the perioperative environment.
Significance: Highlights the emergence of “surgical intelligence” as a distinct health-tech category, combining connected operating rooms, multimodal data and AI to make surgical processes more measurable and potentially more consistent.
Flatiron Health UK has partnered with NHS Greater Glasgow and Clyde, Scotland’s largest health board, to transform routinely collected cancer records into high-quality, research-ready real-world datasets. The collaboration will translate information generated during routine cancer care into structured data that can support oncology research and evidence generation, expanding Flatiron’s network of NHS partnerships beyond England into Scotland for the first time. Significance: Demonstrates how partnerships between health systems and specialist health-data companies are increasingly focused on turning routine clinical data into research infrastructure, potentially allowing evidence generation to represent much larger and more diverse patient populations than conventional clinical trials alone.
Catholic Health and GE HealthCare have announced a 10-year strategic partnership worth approximately $500 million to modernise technology across Catholic Health’s hospitals and ambulatory sites on Long Island. More than 1,300 pieces of technology will be added, spanning imaging, diagnostics and specialised care, alongside AI-enabled tools for scheduling, operations, diagnostics and patient monitoring. The agreement combines large-scale technology deployment with long-term service and operational support.
Significance: Illustrates the shift from individual medical-device purchases towards long-term technology partnerships in which health systems and medtech companies jointly modernise infrastructure, with AI increasingly becoming part of the broader enterprise technology stack rather than a standalone product.
PatientsLikeMe and Science 37 have formed a strategic partnership designed to make it easier for patients to discover and participate in clinical trials. PatientsLikeMe brings its patient community and health-insights platform together with Science 37’s direct-to-patient clinical-trial infrastructure, enabling sponsors to identify relevant patients earlier and support participation through traditional, hybrid and decentralised trial models. The companies are particularly targeting populations that can be difficult to recruit, including geographically dispersed and underserved patients.
Significance:
Shows how digital health is increasingly being used to address one of clinical research’s most persistent problems—patient recruitment—by connecting patient communities, digital engagement and decentralised trial infrastructure.
Lumeris has partnered with Schmitt-Thompson Clinical Content to incorporate evidence-based telehealth triage guidance into Tom, Lumeris’ AI-powered primary-care platform. The integration combines AI-powered symptom checking with established clinical triage content, giving the system a more structured evidence base for assessing symptoms and guiding patients towards appropriate care. The companies say the partnership is intended to improve consistency in patient guidance while helping care teams extend access and provide more proactive support.
Significance: Reflects an important counter-trend to generic generative AI in healthcare: partnerships are increasingly combining AI with curated clinical knowledge and established decision-support frameworks to make AI outputs more clinically grounded and operationally useful.
The AI Centre for Value Based Healthcare, led by King’s College London and Guy’s & St Thomas’ NHS Foundation Trust, is partnering with the University of Cambridge and other NHS trusts to use Cambridge’s new Zenith AI supercomputer for healthcare innovation. The collaboration will use the computing infrastructure to accelerate development of AI applications including predictive analytics, diagnostics and personalised medicine. It brings together academic research, NHS clinical environments and high-performance AI infrastructure.
Significance: Points towards a more infrastructure-led phase of healthcare AI, where universities and health systems are pooling access to advanced computing and clinical data rather than developing AI capabilities independently within individual institutions.
The Gallbladder Cancer Foundation and Citizen Health have expanded their partnership to make Ari, Citizen Health’s AI-powered patient and caregiver assistant, available to people affected by gallbladder cancer. The tool is designed to help patients and families manage the practical and informational burden associated with an aggressive and relatively uncommon cancer, building on the organisations’ existing work together.
Significance: Shows a different application of health AI: rather than targeting clinicians or drug discovery, partnerships are increasingly using AI to provide continuous patient navigation and support in diseases where specialist information and coordinated resources can be difficult to access.
Ransomware gang hijacks AnMed’s Facebook page as attack shutters 83 facilities
AnMed, a nonprofit health system serving upstate South Carolina and northeast Georgia, confirmed on 26 July 2026 that it was experiencing a cybersecurity disruption involving malware, forcing the temporary closure of 83 of its 106 facilities as computer systems, phone lines and internet connectivity went down, though emergency rooms, urgent care and laboratory services stayed open. Patients reported that hospital screens displayed a demand giving AnMed 72 hours to pay before information would be leaked, and two weeks later the system’s Facebook page was apparently hacked to display ransom demands from “The Gentlemen” ransomware group, which claimed — without evidence — to have exfiltrated 6 terabytes of data including records relating to sexual assault, mental health and abortions; ten facilities remained closed as of this week. The incident is significant because it shows extortion tactics escalating from encryption to public humiliation via a victim’s own social channels — and because The Gentlemen has become one of the most prolific ransomware-as-a-service operations since emerging in late 2025.
DentaQuest breach toll passes 15 million as ShinyHunters leaks stolen data
Dental and vision benefits administrator DentaQuest began issuing notification letters on a rolling basis from 17 July 2026 over a cybersecurity incident in which unauthorised parties accessed parts of its network between 17 and 20 May; at least 15 million individuals are confirmed affected, a total that could rise to more than 23.4 million based on an independent researcher’s analysis of the leaked data, and the breach was claimed by the ShinyHunters gang, which published the alleged 234GB cache on its leak site on 30 May after saying negotiations failed. Stolen information includes names, addresses, Social Security numbers, member IDs, Medicaid and Medicare numbers and dental or vision health information. The story matters because it is shaping up as the largest US healthcare breach of 2026, it hit a benefits administrator rather than a hospital — again proving the payer/administrator layer is where records concentrate — and the affected population includes children, with separate notification letters filed for parents of affected minors.
Abbott investigates twin extortion claims against its cancer diagnostics arm
Abbott is investigating claims from two threat groups alleging cyberattacks and data theft — one involving legacy systems of Exact Sciences, the cancer diagnostics business it acquired in late 2025, and another involving its LabCentral customer portal — and has confirmed unauthorised access to certain legacy cancer diagnostics systems, while saying other Abbott businesses and operations were unaffected. ShinyHunters claimed it gained access via a voice-phishing attack on Abbott employees in mid-June that compromised a Microsoft Entra single sign-on account, while a second actor, ShadowByt3$, claimed access from 4 July via compromised customer credentials, and Abbott’s Oregon regulatory filing states the incident was discovered on 8 July, publicly acknowledged on 16 July, with a 5 August update confirming some impacted files contain personal and health information. The case is significant because it shows M&A as a cyber risk vector — the acquirer inheriting the target’s legacy systems — and confirms the industrialisation of identity-based vishing attacks that the same gang has used against Medtronic and other medtech firms.
Oncology software vendor breach ripples out to 442,000 patients
Unlimited Systems, a third-party software vendor serving specialty healthcare practices, began notifying affected individuals on 21 July 2026 following a ransomware attack that exposed the data of roughly 442,000 patients, offering 24 months of free identity monitoring; Iowa’s notice alone covers about 162,000 residents and South Carolina’s about 148,000, though full medical records, imaging and financial account numbers were not involved. The incident is significant because the company is not a household name — a single vendor breach rippled across patients of dozens of unrelated provider organisations, the pattern that has made niche clinical software firms and business associates the preferred entry point for attackers seeking scale.
Loma Linda discloses breach after research data uploaded to external AI platform
Loma Linda University Health announced in August a data breach involving an external AI platform: during an Institutional Review Board-approved research study, a dataset including limited patient information was inadvertently uploaded to the platform, with the investigation determining it included medical record numbers, dates of birth and limited clinical information related to orthopaedic care. The incident is small in scale but significant in kind — it is one of the first named hospital disclosures where the “attacker” is nobody at all, just a researcher and an AI tool. As clinicians and academics adopt generative AI faster than governance can keep up, “shadow AI” uploads are emerging as a new breach category that traditional perimeter security does nothing to prevent — a warning with obvious resonance for every organisation deploying AI in health.
UCLA Health reports 16-month unauthorised disclosure of patient records
UCLA Health reported an incident to the California Attorney General on 4 August 2026 in which patient information was accessed and disclosed to an outside healthcare provider in a manner inconsistent with its own policies, with the state filing identifying disclosure dates spanning December 2024 to April 2026; the health system says it determined the disclosure had occurred in July 2026, and affected data includes names, addresses, dates of birth, health insurance information and clinical information such as referral orders, with partial Social Security digits for some patients. UCLA Health said it has implemented enhanced system controls and increased monitoring, and is unaware of any actual or attempted misuse. This one matters as a governance failure rather than an attack: data flowed improperly for around 16 months before detection, showing that internal access controls and audit of data-sharing arrangements can fail as consequentially as any firewall.
Alabama hospital notifies patients more than a year after network intrusion
Whitfield Regional Hospital in Alabama began notifying patients in July 2026 about a data breach more than a year after detecting unauthorised access to its network, having determined that an unauthorised party had access to parts of its network between 15 May and 8 June 2025, exposing names, dates of birth, Social Security numbers, driver’s licence numbers and medical information. The delay is the story: a 13-month gap between intrusion and patient notification leaves victims exposed to fraud they don’t know to watch for, and illustrates the chronic lag between detection, forensic review and disclosure that regulators on both sides of the Atlantic are increasingly targeting.
We are squeezing the passion to heal out of doctors, nurses, pharmacists and technicians. We are raising the cost of healing while moving further away from preventing disease in the first place...Doctors are people. Highly educated and highly trained people, but they’re still people. We could improve the health system by remembering our humanity.Bestselling author Gil Bashe shares his views on the fractured nature of the healthcare system at a fireside chat hosted in London by Health Tech World.
Teladoc launches Teladoc One, rebuilding virtual care around the whole person
Teladoc Health has announced Teladoc One, described as a fundamentally new model of virtual care that begins with the person rather than the condition, directly addressing the industry’s longstanding problem of fragmented point solutions built to manage one disease at a time instead of dynamically supporting someone’s entire health needs. The launch is significant because it represents the biggest strategic repositioning by the largest telehealth incumbent since the pandemic era: with employers suffering acute “point solution fatigue” and AI-native challengers unbundling virtual care, Teladoc is betting that an integrated, longitudinal care practice — not another menu of condition-specific programmes — is what buyers will pay for next.
Caris Life Sciences launches Caris Detect multi-cancer blood test
Caris Life Sciences, the AI TechBio and precision medicine company, has announced the commercial launch of Caris Detect, a multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages, which the company bills as the world’s most sensitive and comprehensive test of its kind. The launch matters because multi-cancer early detection is one of the most closely watched frontiers in AI-enabled diagnostics — a market where Grail’s Galleri has so far dominated the conversation — and a credible new entrant from a company with a deep molecular profiling database intensifies both the commercial race and the ongoing debate about screening evidence, false positives and who pays.
Luma Health launches Patient Pipeline to turn ad spend into booked appointments
Luma Health has announced Patient Pipeline, a product that uses AI to connect patients shopping for care with health systems’ open capacity — reading a health system’s real-time schedule, building Google Ads around the open slots, then tracing each booking back to the marketing effort that drove it, so marketers can for the first time follow an ad click through to care received and its associated revenue. The launch is significant because it fuses two functions that have always lived apart in health systems — marketing and capacity management — and signals a broader shift in patient-access tech from passive scheduling tools toward AI that actively fills unbooked clinical time.
HOPPR unveils Presto to slot AI draft reporting into existing radiology systems
HOPPR has unveiled its Presto Agent, a solution aimed at simplifying AI integration within existing radiology reporting systems by allowing radiologists to incorporate AI draft reporting capabilities without adopting new platforms or making significant workflow modifications. The launch is notable because integration friction — not algorithm quality — has become the biggest barrier to radiology AI adoption; a vendor-agnostic agent that works inside the reporting tools radiologists already use attacks exactly the pain point that has left many imaging AI deployments stuck at pilot stage.
Relatient expands Dash Voice AI into clinical request automation
Relatient has announced a clinical request automation capability for its Dash Voice AI solution, with the AI voice agent now automatically capturing patients’ clinical, medication, billing and other requests and creating an actionable task for the right care team directly within existing workflow tools such as the EHR. Announced on 22 July, the expansion is significant because it moves healthcare voice AI beyond appointment booking — the first-generation use case — into clinical message triage, the high-volume inbox work that consumes nursing and admin time, and does so by writing directly into the EHR rather than creating another queue for staff to monitor.
Trice Imaging launches Workspace Reporting for obstetrics and maternal-fetal medicine
Trice Imaging has launched Trice Workspace Reporting, a reporting tool built specifically for obstetrics and maternal fetal medicine, designed to address rising pregnancy complexity — driven by advanced maternal age, IVF-assisted pregnancies, rising obesity and higher prevalence of hypertension and diabetes — which means more cases requiring specialist monitoring, advanced imaging and multidisciplinary care at a time when clinical teams are stretched and facing increasing administrative demands. The launch is a useful counterpoint to general-purpose clinical AI: a specialty-specific workflow tool for women’s health, a domain long underserved by health IT investment despite the growing acuity of the caseload.
1upHealth launches 1up Gateway ahead of US interoperability deadline
Interoperability firm 1upHealth has announced the 1up Gateway, a new model to support compliance with the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) among health plans that already have FHIR infrastructure, positioning the broader payer ecosystem ahead of the final 1 January 2027 deadline. The launch matters because CMS-0057-F is the regulatory event forcing US payers to open up prior authorisation and patient data via APIs — and products that turn that compliance burden into deployable infrastructure are where the interoperability market’s near-term revenue now sits, a dynamic with clear read-across to the UK’s own FHIR-based integration push.
Royal Cornwall Hospitals goes live with Modeus’ electronic controlled drug register
Royal Cornwall Hospitals NHS Trust went live on 5 August with HS8, the electronic controlled drug register from Australian software firm Modeus, replacing paper-based registers in the Trust’s pharmacy with a single, closed-loop digital system giving real-time visibility of controlled drug stock, movements and discrepancies — the first stage of a rollout that will extend to wards and theatres. The go-live is significant as a marker of Modeus’ entry into the NHS market and of a wider, unglamorous but consequential trend: the digitisation of high-risk paper workflows (controlled drugs being among the most heavily regulated) where audit trails and transcription-error reduction deliver immediate patient safety and compliance gains.
Health Tech World is part of Aspect Health Media Ltd, a specialist healthcare publisher focused on contributing to better patient outcomes through news, insights and the sharing of ideas. Other Aspect publications include Femtech World, for all the innovators working to close the gender health gap, Agetech World, which covers the global longevity sector, and Neuro Rehab Times, dedicated to brain and spinal professionals globally.
www.aspecthealthmedia.com
Aspect Health Media Ltd (Company Registration No: 10109188), 3 Berrymoor Court, Northumberland Business Park, Cramlington, Northumberland, United Kingdom, NE23 7RZ.